Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 59,200 shares, a decrease of 14.7% from the September 30th total of 69,400 shares. Based on an average trading volume of 43,400 shares, the days-to-cover ratio is currently 1.4 days. Approximately 2.1% of the shares of the stock are short sold.

Senti Biosciences Stock Performance

Shares of NASDAQ SNTI traded up $0.09 during trading on Monday, reaching $2.24. The company had a trading volume of 6,276 shares, compared to its average volume of 240,048. Senti Biosciences has a 52 week low of $1.52 and a 52 week high of $8.48. The business's 50 day moving average price is $2.54 and its 200-day moving average price is $2.80. The stock has a market cap of $102.49 million, a PE ratio of -1.56 and a beta of 2.75.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($2.45) earnings per share for the quarter. Equities analysts anticipate that Senti Biosciences will post -10 earnings per share for the current year.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.